Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Royalty Pharma plcRPRX · Entity 3100 | EVP & CFO | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Royalty Pharma plc
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectTPC RP EPA1 LLC | 1,772 |
Reported balance
After 2026-08-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-13 · Sale · Disposed 9,230 · Balance 1,772 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.99 to $58.98 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectTPC RP EPA1 LLC | 0 |
Reported balance
After 2026-08-13 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-13 · Sale · Disposed 1,772 · Balance 0 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.98 to $59.52 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse's IRA | 24,170 |
Reported balance
Holding disclosure · report date 2026-08-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 24,170 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy IRA | 23,270 |
Reported balance
Holding disclosure · report date 2026-08-13 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 23,270 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 1,450 |
Reported balance
Holding disclosure · report date 2026-08-13 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,450 |
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 1,500 |
Reported balance
Holding disclosure · report date 2026-08-13 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,500 |
Filing footnotes · ownership attribution and instrument terms
F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.99 to $58.98 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.98 to $59.52 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 17, 2026 21:01 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,772 | $59.14 | $104,798.74 |
DisclosureSEC source: 0001814876-26-000027 · wk-form4_1787000470.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 0 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.98 to $59.52 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 21:01 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 9,230 | $58.59 | $540,752.47 |
DisclosureSEC source: 0001814876-26-000027 · wk-form4_1787000470.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 1,772 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.99 to $58.98 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 21:24 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftClass E Ordinary Shares · Derivative | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001814876-26-000025 · wk-form4_1786137851.xml · derivative · entry 6 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (2) Disclosed balance after: 1,788,777 Underlying: Class A Ordinary Shares · 18,500 shares Expires not disclosed F2 · derivative.exercise_price: No Class E Ordinary Shares of RPH ("Class E Shares") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · derivative.exercise_date: No Class E Ordinary Shares of RPH ("Class E Shares") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · derivative.expiration_date: No Class E Ordinary Shares of RPH ("Class E Shares") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · derivative.underlying_shares: No Class E Ordinary Shares of RPH ("Class E Shares") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · balance_after: No Class E Ordinary Shares of RPH ("Class E Shares") are being converted by the Reporting Person. Class E Shares are subject to vesting conditions. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 21:24 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 11,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001814876-26-000025 · wk-form4_1786137851.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 11,002 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:48 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 64,399 | $53.98 | $3,476,116.34 |
DisclosureSEC source: 0001814876-26-000022 · wk-form4_1780001297.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 0 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.63 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2026 Filed May 8, 2026 21:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 24,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001814876-26-000020 · wk-form4_1778274879.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 64,399 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,875 | $49.78 | $93,334.50 |
DisclosureSEC source: 0001814876-26-000018 · wk-form4_1777586044.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 40,136 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.46 to $50.18 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 32,916 | $49.78 | $1,638,505.81 |
DisclosureSEC source: 0001814876-26-000018 · wk-form4_1777586044.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 0 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.46 to $50.18 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:58 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 32,916 | $48.33 | $1,590,889.53 |
DisclosureSEC source: 0001814876-26-000016 · wk-form4_1775167135.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 32,916 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $48.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:58 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,875 | $48.33 | $90,622.13 |
DisclosureSEC source: 0001814876-26-000016 · wk-form4_1775167135.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 42,011 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $48.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:05 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,875 | $45.53 | $85,366.31 |
DisclosureSEC source: 0001814876-26-000014 · wk-form4_1774472720.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 43,886 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.30 to $45.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:05 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 32,916 | $45.53 | $1,498,622.69 |
DisclosureSEC source: 0001814876-26-000014 · wk-form4_1774472720.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 65,832 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.30 to $45.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 583 | $47.01 | $27,409.34 |
DisclosureSEC source: 0001814876-26-000012 · wk-form4_1772662304.xml · nonDerivative · entry 4 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 45,761 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,292 | $46.67 | $60,303.71 |
DisclosureSEC source: 0001814876-26-000012 · wk-form4_1772662304.xml · nonDerivative · entry 3 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 46,344 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 10,429 | $47.01 | $490,314.22 |
DisclosureSEC source: 0001814876-26-000012 · wk-form4_1772662304.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 98,748 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 22,487 | $46.67 | $1,049,506.52 |
DisclosureSEC source: 0001814876-26-000012 · wk-form4_1772662304.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 109,177 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:08 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,875 | $45.32 | $84,968.44 |
DisclosureSEC source: 0001814876-26-000010 · wk-form4_1772053705.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 47,636 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.60 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:08 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 32,916 | $45.32 | $1,491,637.91 |
DisclosureSEC source: 0001814876-26-000010 · wk-form4_1772053705.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 131,664 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.60 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:03 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 26,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001814876-26-000008 · wk-form4_1771016592.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 49,511 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| February 04, 2026 Filed Feb 4, 2026 22:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,087 | $43.29 | $47,059.27 |
DisclosureSEC source: 0001814876-26-000006 · wk-form4_1770242855.xml · nonDerivative · entry 6 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 22,885 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.11 to $43.51 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 04, 2026 Filed Feb 4, 2026 22:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 19,076 | $43.29 | $825,853.45 |
DisclosureSEC source: 0001814876-26-000006 · wk-form4_1770242855.xml · nonDerivative · entry 3 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 164,580 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.11 to $43.51 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 22:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 6,195 | $42.84 | $265,413.00 |
DisclosureSEC source: 0001814876-26-000006 · wk-form4_1770242855.xml · nonDerivative · entry 5 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 23,972 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.35 to $43.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 22:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 108,759 | $42.84 | $4,659,583.59 |
DisclosureSEC source: 0001814876-26-000006 · wk-form4_1770242855.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 183,656 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.35 to $43.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 5,843 | $42.08 | $245,896.23 |
DisclosureSEC source: 0001814876-26-000006 · wk-form4_1770242855.xml · nonDerivative · entry 4 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 30,167 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.45 to $42.37 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 102,581 | $42.08 | $4,317,008.55 |
DisclosureSEC source: 0001814876-26-000006 · wk-form4_1770242855.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 292,415 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.45 to $42.37 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 21:48 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,750 | $39.35 | $147,556.50 |
DisclosureSEC source: 0001814876-26-000004 · wk-form4_1769204910.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 36,010 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.86 to $39.66 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 21:48 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 65,832 | $39.35 | $2,590,383.87 |
DisclosureSEC source: 0001814876-26-000004 · wk-form4_1769204910.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 394,996 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.86 to $39.66 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,750 | $38.42 | $144,058.88 |
DisclosureSEC source: 0001814876-26-000002 · wk-form4_1767734318.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 39,760 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $38.64 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 65,832 | $38.42 | $2,528,982.36 |
DisclosureSEC source: 0001814876-26-000002 · wk-form4_1767734318.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 460,828 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $38.64 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:39 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,750 | $38.36 | $143,850.38 |
DisclosureSEC source: 0001814876-25-000011 · wk-form4_1766011182.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 43,510 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $38.48 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:39 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 65,832 | $38.36 | $2,525,322.10 |
DisclosureSEC source: 0001814876-25-000011 · wk-form4_1766011182.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 526,660 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $38.48 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,750 | $39.87 | $149,497.50 |
DisclosureSEC source: 0001814876-25-000009 · wk-form4_1764799875.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 47,260 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · balance_after: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 65,832 | $39.87 | $2,624,458.51 |
DisclosureSEC source: 0001814876-25-000009 · wk-form4_1764799875.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 592,492 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · balance_after: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:01 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 624 | $37.96 | $23,686.73 |
DisclosureSEC source: 0001814876-25-000007 · wk-form4_1764194502.xml · nonDerivative · entry 4 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 51,010 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:01 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,126 | $38.67 | $120,882.11 |
DisclosureSEC source: 0001814876-25-000007 · wk-form4_1764194502.xml · nonDerivative · entry 3 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 51,634 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:01 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 10,686 | $37.96 | $405,644.83 |
DisclosureSEC source: 0001814876-25-000007 · wk-form4_1764194502.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 658,324 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:01 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 55,146 | $38.67 | $2,132,291.78 |
DisclosureSEC source: 0001814876-25-000007 · wk-form4_1764194502.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 669,010 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:53 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,750 | $39.30 | $147,390.00 |
DisclosureSEC source: 0001814876-25-000005 · wk-form4_1763589210.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 54,760 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.97 to $39.50 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:53 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 65,844 | $39.30 | $2,587,939.16 |
DisclosureSEC source: 0001814876-25-000005 · wk-form4_1763589210.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 724,156 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.97 to $39.50 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 6,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001814876-25-000003 · wk-form4_1762550332.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 58,510 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| August 08, 2025 Filed Aug 8, 2025 20:58 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftLP interests in RPI US Partners 2019, LP · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000104 · wk-form4_1754686694.xml · derivative · entry 7 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By TPC ICAI, LLC Disclosed balance after: 43,350 Underlying: Class A Ordinary Shares · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:58 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 3,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000104 · wk-form4_1754686694.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 52,342 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:52 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass E Ordinary Shares · Derivative | 1,807,277 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000067 · wk-form4_1747774366.xml · derivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1)(2) Disclosed balance after: 1,807,277 Underlying: Class A Ordinary Shares · 1,807,277 shares Expires not disclosed F1 · shares: Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as many be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto. F2 · derivative.exercise_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · derivative.expiration_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · derivative.underlying_shares: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · balance_after: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. Read SEC document |
| May 08, 2025 Filed May 9, 2025 21:10 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 48,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000033 · wk-form4_1746825035.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · TPC RP EPA1 LLC Disclosed balance after: 48,646 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| August 12, 2024 Filed Aug 12, 2024 23:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftICAI Interests · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-24-000051 · wk-form4_1723504825.xml · derivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By TPC ICAI, LLC Disclosed balance after: 44,350 Underlying: LP interests in RPI US Partners 2019, LP · 2,000 shares Expires not disclosed F1 · derivative.exercise_price: No ICAI Interests or limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. ICAI Interests represent a grant of an equivalent number of limited partnership interest in RPI US LP ("RPI US LP Interest"). Each RPI US LP Interest may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. F2 · kind: The Reporting Person made a charitable donation of ICAI Interests. No Class A Ordinary Shares, RPI US LP Interests or ICAI Interests were sold. F3 · derivative.exercise_date: Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 21:00 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 37,500 | $30.75 | $1,153,091.25 |
DisclosureSEC source: 0001209191-23-045463 · doc4.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 790,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.55 to $31.07 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 21:00 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 37,500 | $30.72 | $1,151,936.25 |
DisclosureSEC source: 0001209191-23-045463 · doc4.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 827,500 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.41 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2023 Filed Aug 8, 2023 21:37 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftICAI Interests · Derivative | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045064 · doc4.xml · derivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By TPC ICAI, LLC Disclosed balance after: 46,350 Underlying: Limited Partnership interests in RPI US Partners 2019, LP · 1,650 shares Expires not disclosed F1 · derivative.exercise_price: No ICAI Interests or limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. ICAI Interests represent a grant of an equivalent number of limited partnership interest in RPI US LP ("RPI US LP Interest"). Each RPI US LP Interest may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. F2 · kind: The Reporting Person made a charitable donation of ICAI Interests. No Class A Ordinary Shares, RPI US LP Interests or ICAI Interests were sold. F3 · derivative.exercise_date: Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| July 13, 2023 Filed Jul 14, 2023 22:09 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 37,500 | $30.93 | $1,159,957.50 |
DisclosureSEC source: 0001209191-23-042297 · doc4.xml · nonDerivative · entry 2 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 865,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.77 to $31.44 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 22:09 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 37,500 | $31.07 | $1,165,256.25 |
DisclosureSEC source: 0001209191-23-042297 · doc4.xml · nonDerivative · entry 1 Coyne Terrance P. · CIK 0001814876 · EVP & CFO 10b5-1 filing: Plan reported Ownership: Indirect · By TPC RP 2021, LLC Disclosed balance after: 902,500 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.79 to $31.43 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.